Evidence map›Paper›PMID 42003587›Full record

ArticleMicrobiology spectrum2026

Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention.

J A Fernández Romero, P Barnable, M L Visciano, M Aravantinou, A Meyer, S Grecky, F Schiro, B Grasperge, J Gadsden, N Kommineni and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

J A Fernández RomeroScience Department, Borough of Manhattan Community College, The City University of New York, New York, New York, USA.
P BarnableCenter for Biomedical Research, Population Council, New York, New York, USA.
M L ViscianoCenter for Biomedical Research, Population Council, New York, New York, USA.
M AravantinouCenter for Biomedical Research, Population Council, New York, New York, USA.
A MeyerCenter for Biomedical Research, Population Council, New York, New York, USA.
S GreckyCenter for Biomedical Research, Population Council, New York, New York, USA.
F SchiroTulane National Primate Research Center, Covington, Louisiana, USA.
B GraspergeTulane National Primate Research Center, Covington, Louisiana, USA.
J GadsdenCenter for Biomedical Research, Population Council, New York, New York, USA.
N KommineniCenter for Biomedical Research, Population Council, New York, New York, USA.
P AngsantikulCenter for Biomedical Research, Population Council, New York, New York, USA.
N KumarCenter for Biomedical Research, Population Council, New York, New York, USA.
J NuttallCenter for Biomedical Research, Population Council, New York, New York, USA.
L B HaddadCenter for Biomedical Research, Population Council, New York, New York, USA.ORCID 0000-0002-7631-6760
N TeleshovaCenter for Biomedical Research, Population Council, New York, New York, USA.ORCID 0000-0003-3169-4650

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
NIH HHS P51 OD011104U.S. Agency for International Development Cooperative Agreement #7200AA22CA00002
6 · The paper itself

Abstract

Griffithsin (GRFT) is an antiviral lectin that blocks human immunodeficiency virus (HIV) entry. When combined with carrageenan (CG), GRFT has strong activity against herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV). We conducted a preclinical evaluation of a high-dose vaginal fast-dissolving insert (FDI) containing 3 mg GRFT-equivalent to 3× the clinical dose-and compared it with a 1 mg formulation. Studies included FDI disintegration (macaques, rabbits); GRFT pharmacokinetics, pharmacodynamics, and inflammatory response (macaques); toxicity (rats); and immunogenicity (macaques, rats). Disintegration times varied between species, emphasizing the importance of evaluating this parameter in humans. In macaques, cervico-vaginal lavage (CVL) GRFT concentrations exceeded levels associated with

Indexed as

Antiviral AgentsCarrageenanHIV InfectionsPapillomavirus InfectionsPlant LectinsAdministration, IntravaginalAnimalsDrug Evaluation, PreclinicalFemaleHerpes GenitalisHerpesvirus 2, HumanHuman Papillomavirus VirusesHumansMacacaRabbitsRatsAntiviral AgentsCarrageenangriffithsin protein, GriffithsiaPlant Lectinsfast-dissolving insertGriffithsinHIVHPVHSV-2

Identifiers

PMID42003587
PMCPMC13228069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.